Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04561453 · ClinicalTrials.gov registry record
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
A clinical trial, sponsored by University of Washington.
- Terminated
- Registry status
- 14
- Enrollment target
NCT04561453 is a clinical trial that was terminated before completion, run by University of Washington. The registered enrollment target is 14 participants.
The verdict
NCT04561453 was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This study is going to test the ability to successfully obtain results from certain personalized tests for patients with biliary tract cancers that are able to be surgically removed. Through surveys, this study will also evaluate the usefulness of these tests to medical oncologists as they make decisions on what standard or experimental treatments might benefit the patient's enrolled in the study. The study is observational and does not require any change in the standard approach to treating biliary tract cancer. Results of the personalized tests will be provided to the treating medical oncologist and the medical oncologist can choose to whether or not to change management based on these results. These personalized tests include reading of the cancer DNA, testing whether a panel of drugs can kill a patient's cancer cells in a test tube, and testing for small amounts of cancer DNA in the blood as a way to check for the presence of leftover cancer in the body after it is removed surgically. This study will also give extra pieces of cancer, that would otherwise be discarded, from surgery for laboratory research into how biliary tract cancers respond to drugs and the body's immune system. The investigators hypothesize that the drug screen test will, in some cases, be useful to the medical oncologist and may lead to the use of cancer drugs that would not otherwise have been chosen based on standard guidelines or based on cancer DNA testing. The investigators hypothesize that the test tube drug screening method will correlate with how the cancer responds to the drugs in real life for those patients that end up receiving a drug that was included in the drug screen panel. The investigators hypothesize that monitoring of cancer DNA in the blood stream will help us predict which patients are most likely to have their cancer return after surgery. The investigators also hypothesize that in many cases the appearance of cancer DNA in the blood stream will happen weeks to months p
Interventions
- DIAGNOSTIC_TEST Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2025-04-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04561453
The ClinicalTrials.gov registry entry for NCT04561453 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring is the first listed.
NCT04561453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04561453 about?
NCT04561453 is a clinical study titled "Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer". This study is going to test the ability to successfully obtain results from certain personalized tests for patients with biliary tract cancers that are able to be surgically removed. Through surveys, this study will also evaluate the usefulness of these tests to medical oncologists as they make deci...
What is the current status of trial NCT04561453?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2020-07-08. Estimated completion is 2025-04-04.
What interventions are being tested in trial NCT04561453?
The interventions under investigation include: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04561453?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.